DUBLIN--(BUSINESS WIRE)--The "Acute Respiratory Distress Syndrome - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
This pharmaceutical and healthcare disease pipeline guide provides an overview of the Acute Respiratory Distress Syndrome (Respiratory) pipeline landscape.
Acute respiratory distress syndrome (ARDS) occurs when fluid fills up the air sacs in lungs. This leads to low oxygen levels in the blood. Common causes of ARDS include sepsis, inhalation of harmful substances, severe pneumonia and head or chest injury. Signs and symptoms of ARDS include severe shortness of breath, labored and unusually rapid breathing, low blood pressure and confusion and extreme tiredness.
The latest pipeline guide provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The pipeline guide also reviews of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 6, 15 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
The guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope of the report:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome.
- The pipeline guide reviews pipeline therapeutics for Acute Respiratory Distress Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Respiratory Distress Syndrome therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome.
Key report benefits:
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Respiratory Distress Syndrome.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
- Acute Respiratory Distress Syndrome - Overview
- Acute Respiratory Distress Syndrome - Therapeutics Development
- Acute Respiratory Distress Syndrome - Therapeutics Assessment
- Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics Development
- Acute Respiratory Distress Syndrome - Drug Profiles
- Acute Respiratory Distress Syndrome - Dormant Projects
- Acute Respiratory Distress Syndrome - Discontinued Products
- Acute Respiratory Distress Syndrome - Product Development Milestones
- A6 Pharmaceuticals LLC
- Aqualung Therapeutics Corp
- Athersys Inc
- Bayer AG
- Cells for Cells SA
- Commence Bio Inc
- Cynata Therapeutics Ltd
- Emergent BioSolutions Inc
- Eunoia Biotech LLC
- Exvastat Ltd
- Faron Pharmaceuticals Oy
- Histocell SL
- Hydra Biosciences Inc
- Implicit Bioscience Ltd
- In2cure AB
- IsletOne AB
- Liminal BioSciences Inc
- LTT Bio-Pharma Co Ltd
- Meridigen Biotech Co Ltd
- Nano Biotherapeutics Inc
- Northern Therapeutics Inc
- Orbsen Therapeutics Ltd
- Restore Therapeutics LLC
- Savara Inc
- SolAeroMed Inc
- Vasomune Inc
- Windtree Therapeutics Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/9am7wp.
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.